The University of Chicago Header Logo

Connection

Stephen Archer to Middle Aged

Back to Details
This is a "connection" page, showing publications Stephen Archer has written about Middle Aged.
Stephen Archer
Connection Strength
0.616
Middle Aged
  1. Novel Drp1 GTPase Inhibitor, Drpitor1a: Efficacy in Pulmonary Hypertension. Hypertension. 2024 Oct; 81(10):2189-2201.
    View in: PubMed
    Score: 0.061
  2. Carvedilol for Treatment of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. J Am Heart Assoc. 2021 07 20; 10(14):e021518.
    View in: PubMed
    Score: 0.050
  3. An epigenetic increase in mitochondrial fission by MiD49 and MiD51 regulates the cell cycle in cancer: Diagnostic and therapeutic implications. FASEB J. 2020 04; 34(4):5106-5127.
    View in: PubMed
    Score: 0.045
  4. Home Virtual Visits for Outpatient Follow-Up Stroke Care: Cross-Sectional Study. J Med Internet Res. 2019 10 07; 21(10):e13734.
    View in: PubMed
    Score: 0.044
  5. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018 02; 11(2):e003973.
    View in: PubMed
    Score: 0.039
  6. Atrioventricular heart block and syncope coincident with diagnosis of systemic lupus erythematosus. Can J Cardiol. 2013 Oct; 29(10):1330.e5-1330.e7.
    View in: PubMed
    Score: 0.029
  7. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 2013 Aug 10; 167(3):669-76.
    View in: PubMed
    Score: 0.026
  8. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010 Nov; 138(5):1234-9.
    View in: PubMed
    Score: 0.024
  9. Cardiac EASE (Ensuring Access and Speedy Evaluation) - the impact of a single-point-of-entry multidisciplinary outpatient cardiology consultation program on wait times in Canada. Can J Cardiol. 2009 Dec; 25(12):697-702.
    View in: PubMed
    Score: 0.022
  10. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med. 2009 Nov 05; 361(19):1864-71.
    View in: PubMed
    Score: 0.022
  11. Differences in food habits and cardiovascular disease risk factors among Native Americans with and without diabetes: the Inter-Tribal Heart Project. Public Health Nutr. 2004 Dec; 7(8):1025-32.
    View in: PubMed
    Score: 0.016
  12. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med. 2004 Mar 08; 164(5):514-20.
    View in: PubMed
    Score: 0.015
  13. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003 Oct 28; 108(17):2066-9.
    View in: PubMed
    Score: 0.015
  14. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002 May 21; 105(20):2398-403.
    View in: PubMed
    Score: 0.013
  15. Endothelial BMPR2 Loss Drives a Proliferative Response to BMP (Bone Morphogenetic Protein) 9 via Prolonged Canonical Signaling. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2605-2618.
    View in: PubMed
    Score: 0.012
  16. Excess Protein O-GlcNAcylation Links Metabolic Derangements to Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. Int J Mol Sci. 2020 Oct 01; 21(19).
    View in: PubMed
    Score: 0.012
  17. Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation. 2020 06 16; 141(24):1986-2000.
    View in: PubMed
    Score: 0.011
  18. Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension. J Am Heart Assoc. 2020 03 03; 9(5):e015221.
    View in: PubMed
    Score: 0.011
  19. Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respir Med. 2019 03; 7(3):227-238.
    View in: PubMed
    Score: 0.010
  20. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med. 1998 Oct; 158(4):1061-7.
    View in: PubMed
    Score: 0.010
  21. Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide. J Heart Lung Transplant. 2019 02; 38(2):145-155.
    View in: PubMed
    Score: 0.010
  22. Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension. Am J Respir Crit Care Med. 2018 06 01; 197(11):1496-1499.
    View in: PubMed
    Score: 0.010
  23. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant. 2018 03; 37(3):376-384.
    View in: PubMed
    Score: 0.009
  24. Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation. 2015 Jan 27; 131(4):401-9; discussion 409.
    View in: PubMed
    Score: 0.008
  25. Usefulness of mean aortic valve gradient and left ventricular diastolic filling pattern for distinguishing symptomatic from asymptomatic patients. Am J Cardiol. 1994 Feb 01; 73(4):275-81.
    View in: PubMed
    Score: 0.007
  26. Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur Respir J. 2013 Jul; 42(1):125-33.
    View in: PubMed
    Score: 0.007
  27. Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology. 2012 Oct; 61(4):597-609.
    View in: PubMed
    Score: 0.007
  28. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012 Feb 01; 14:11.
    View in: PubMed
    Score: 0.006
  29. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011 Nov; 13(11):1231-7.
    View in: PubMed
    Score: 0.006
  30. Five-year follow-up of a multicenter, double-blind randomized clinical trial of laparoscopic Nissen vs anterior 90 degrees partial fundoplication. Arch Surg. 2010 Jun; 145(6):552-7.
    View in: PubMed
    Score: 0.006
  31. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010 May; 35(5):1079-87.
    View in: PubMed
    Score: 0.006
  32. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010 Mar; 87(3):303-10.
    View in: PubMed
    Score: 0.006
  33. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb; 29(2):181-7.
    View in: PubMed
    Score: 0.005
  34. The association between erectile dysfunction and peripheral arterial disease as determined by screening ankle-brachial index testing. Atherosclerosis. 2009 Dec; 207(2):440-4.
    View in: PubMed
    Score: 0.005
  35. Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail. 2009 Jul; 2(4):278-86.
    View in: PubMed
    Score: 0.005
  36. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation. 2008 May 13; 117(19):2475-83.
    View in: PubMed
    Score: 0.005
  37. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007 Jul 17; 116(3):238-48.
    View in: PubMed
    Score: 0.005
  38. Exercise thallium testing in ventricular preexcitation. Am J Cardiol. 1987 May 01; 59(12):1103-6.
    View in: PubMed
    Score: 0.005
  39. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006 Nov; 13(21):1503-11.
    View in: PubMed
    Score: 0.004
  40. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005 Jun; 115(6):1479-91.
    View in: PubMed
    Score: 0.004
  41. Case 2. Recurrence of myocardial infarction. Can J Cardiol. 2000 Aug; 16 Suppl E:24E-26E.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.